Cargando…

Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy

PURPOSE: To investigate the 2-year outcomes of three monthly intravitreal ranibizumab injections followed by as-needed reinjections to treat polypoidal choroidal vasculopathy (PCV). METHODS: Seventy-five consecutive eyes with naïve symptomatic PCV with 2 years of follow-up after treatment were studi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hikichi, Taiichi, Higuchi, Makoto, Matsushita, Takuro, Kosaka, Shoko, Matsushita, Reiko, Takami, Kimitaka, Ohtsuka, Hideo, Kitamei, Hirokuni, Shioya, Shoko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2013
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632979/ https://www.ncbi.nlm.nih.gov/pubmed/23428984 http://dx.doi.org/10.1136/bjophthalmol-2012-302652

Ejemplares similares

Retinal pigment epithelial atrophy over polypoidal choroidal vasculopathy lesions during ranibizumab monotherapy
por: Hikichi, Taiichi, et al.
Publicado: (2016)

Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion
por: Hikichi, Taiichi, et al.
Publicado: (2014)

Intraoperative endoscopic observation of sclerotomy site after cannula removal for 23-gauge vitrectomy
por: Hikichi, Taiichi, et al.
Publicado: (2014)

Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy
por: Hikichi, Taiichi
Publicado: (2015)

Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy
por: Gu, Xiaoya, et al.
Publicado: (2019)

Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab
por: Sonoda, Shozo, et al.
Publicado: (2013)

Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
por: Miura, Masahiro, et al.
Publicado: (2013)

Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence
por: Soman, Manoj, et al.
Publicado: (2022)

Reduction in choroidal thickness of macular area in polypoidal choroidal vasculopathy patients after intravitreal ranibizumab therapy
por: Nishide, Tadayuki, et al.
Publicado: (2013)

Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy
por: Nemoto, Rei, et al.
Publicado: (2012)

Short-Term Outcomes of Switching to Ranibizumab in Polypoidal Choroidal Vasculopathy Resistant to Aflibercept Therapy
por: Jeon, Young-Joon, et al.
Publicado: (2021)

Polypoidal Choroidal Vasculopathy in Asians
por: Wong, Chee Wai, et al.
Publicado: (2015)

One-year outcomes of intravitreal brolucizumab injections in patients with polypoidal choroidal vasculopathy
por: Ito, Arisa, et al.
Publicado: (2022)

Short-term Effectiveness of Intravitreal Bevacizumab vs. Ranibizumab Injections for Patients with Polypoidal Choroidal Vasculopathy
por: Cho, Han Joo, et al.
Publicado: (2012)

1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy
por: Wong, Ian Y., et al.
Publicado: (2015)

Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2017)

Choroidal Nevus in an Eye with Polypoidal Choroidal Vasculopathy
por: Asao, Kazunobu, et al.
Publicado: (2014)

Eplerenone in the Treatment of Polypoidal Choroidal Vasculopathy
por: Kapoor, Kapil G., et al.
Publicado: (2015)

Polypoidal Choroidal Vasculopathy in Congolese Patients
por: Kabedi, Nelly N., et al.
Publicado: (2020)

Early Responses to Intravitreal Ranibizumab in Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
por: Matsumiya, Wataru, et al.
Publicado: (2011)

One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy
por: Sakurai, Madoka, et al.
Publicado: (2014)

Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab
por: Yamashita, Mariko, et al.
Publicado: (2014)

Practicability confirmation by meta-analysis of intravitreal ranibizumab compared to photodynamic therapy to treat polypoidal choroidal vasculopathy
por: Liu, Ling, et al.
Publicado: (2015)

Comparison of one-year results of photodynamic therapy combined with ranibizumab or aflibercept for treating polypoidal choroidal vasculopathy
por: Ito, Arisa, et al.
Publicado: (2020)

Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Wataru, Kikushima, et al.
Publicado: (2020)

Evolution of Polypoidal Lesions after Treatment of Polypoidal Choroidal Vasculopathy
por: Tan, Colin S., et al.
Publicado: (2021)

Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response
por: Hatz, Katja, et al.
Publicado: (2014)

Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy Controversy Concerning Long-Term Followup
por: Fernández, Maribel, et al.
Publicado: (2012)

Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen
por: Lai, Kunbei, et al.
Publicado: (2018)

Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports
por: Iesato, Yasuhiro, et al.
Publicado: (2018)

Long-Term Follow-Up of Polypoidal Choroidal Vasculopathy Secondary to Angioid Streaks Treated by Intravitreal Aflibercept and Ranibizumab
por: Wong, James G., et al.
Publicado: (2017)

Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial
por: Lim, Tock H., et al.
Publicado: (2020)

Association between pachychoroid and long-term treatment outcomes of photodynamic therapy with intravitreal ranibizumab for polypoidal choroidal vasculopathy
por: Azuma, Keiko, et al.
Publicado: (2020)

Correction: Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2020)

Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Jin, Ki Won, et al.
Publicado: (2021)

SERPING1 polymorphisms in polypoidal choroidal vasculopathy
por: Li, Meng, et al.
Publicado: (2010)

Disadvantages of photodynamic therapy for polypoidal choroidal vasculopathy
por: Chhablani, Jay Kumar
Publicado: (2010)

Polypoidal Choroidal Vasculopathy: An Update on Therapeutic Approaches
por: Wong, Raymond L.M., et al.
Publicado: (2013)

Treatment Outcomes in Patients with Polypoidal Choroidal Vasculopathy
por: Sayman Muslubaş, Işıl, et al.
Publicado: (2016)

Macular Hole Secondary to Polypoidal Choroidal Vasculopathy
por: Baskaran, Prabu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_u4ikbklir9s1ms2v2nn7ube80q